Dow Jones
38.854,01 +178,33 (+0,46%) Nasdaq
16.303,59 +147,26 (+0,91%) Nikkei 225
38.236,07 -38,03 (-0,10%) EUR/USD
1,0777 +0,0010 (+0,10%) Bitcoin EUR
58.679,18 -760,73 (-1,28%) CMC Crypto 200
1.361,70 +49,07 (+3,74%)
INCY May 2024 65.000 put
| Chiusura precedente | 11,94 |
| Aperto | 11,73 |
| Denaro | 10,40 |
| Lettera | 12,80 |
| Prezzo d'esercizio | 65,00 |
| Scadenza | 2024-05-17 |
| Min-Max giorno | 11,64 - 12,21 |
| Contratto - Min-Max | N/D |
| Volume | |
| Open Interest | N/D |
GlobeNewswireGlobal CAR T-cell Therapy Market Projected to Reach $83 Billion by 2032
PALM BEACH, Fla., Oct. 12, 2023 (GLOBE NEWSWIRE) -- FinancialNewsMedia.com News Commentary - Significant influences driving the CAR T-cell therapy market is a rising demand for model therapeutics for treatment of cancer, increase in prevalence of cancer and an escalating awareness of CAR T-cell therapy medicines. The CAR T-cell therapy market is currently going through a rapid expansion, owing to rapidly expanding clinical trial activities and recent commercialization of CAR-T cell therapy, whic
GlobeNewswireKnight Therapeutics Announces Regulatory Submission of Pemigatinib in Brazil
MONTREAL, Oct. 10, 2023 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that its Brazilian affiliate, United Medical Ltd., has submitted a marketing authorization application for pemigatinib to ANVISA, the Brazilian health regulatory agency, under the rare diseases approval pathway, for the treatment of adults with locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor recepto
